Patents

Tabla de patentes
Code	Description	Priority
98002	Interferon alfa 5 use as antiviral for hepatitis C treatment	Sol. ES981003 (3/5/1998)
98003	Peptide inhibitors of TGF beta 1	Sol. ES9802465 (24/11/1998)
01008	Use of Cardiotrophine (CT-1) for the treatment of human liver diseases	Sol. ES200102120 (21/9/2001)
02007	Peptides Inhibitors of TGF-beta 1 (II)	Sol. ES200302020 (22/8/2003)
03001	New method for thrombosis risk evaluation by measuring e PCR auto-antibody in plasma	Sol. ES200400269 (06/02/2004)
03004	Hybrid virus (Adenovirus-alfa/ Semliki Forest) to administer and express therapeutics genes in tumour cells	Sol. ES200401219 (20/05/2004)
04005	Use of anfirreguline as acute liver protectant agent	Sol. ES200401776 (20/07/2004)
04011	Oxidised Apo A1 as early markers of Hepatocellular carcinoma	Sol. ES200402989 (16/12/2004)
04007	New soluble ePCR protein as trombotic marker and potential therapeutic agent	Sol. ES 200500623 (17/03/2005)
04016	5'-metiltioadenosina (MTA) in the prevention and treatment of autoimmune diseases	PCT/ES 2005/000139 (17/03/2005)
04012	Use of C-aminoterminal fragment of cardiotrofina-1 as marker of cardiac insufficiency	PCT/ES 2005/000227 (28/04/2005)
05008	Use of cardiotrofina-1 (CT-1) and alfa interferon (IFNa) for combined treatment in viral diseases	Sol. ES200501468 (16/06/2005)
05012	Fibrosis markers in urine	Sol. ES200501611 (01/07/2005)
04018	Use of EDA as immune-modulator agent	Sol. ES200501412 (13/06/2005)
05013	A selection of hepatocellular carcinoma markers	Sol. ES200502369 (29/09/2005)
05009	Immune-stimulatory combination for hepatitis C prevention	Sol. ES200502446 (07/10/2005) Sol. ES200601563 (09/06/2006)
05030	Use of peptides inhibitor of TGF-beta1 as a immune response modulator	PCT/ES 2005/002446 (24/10/2005)
05019	New recombinant adenovirus with conditionated replication	Sol. ES200503047 (12/12/2005)
05025	Use of inhibitory peptides of TGFb for the treatment of bond metastasis	Sol ES20060223923/08/2006